Can special contacts or atropine drops slow nearsightedness in kids?
NCT ID NCT05815784
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial tests three approaches to slow the progression of nearsightedness (myopia) in children aged 5 to 12: daily atropine eye drops, MiSight contact lenses, and NaturalVue multifocal contact lenses. Over two years, researchers will measure changes in eye length and prescription strength to see which method works best. The study also looks at how well younger children tolerate contact lenses and how consistently each treatment is used.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- atropine 0.05% eye drops, MiSight contact lenses, or NaturalVue multifocal contact lenses
- What this could lead to
- If successful, this could identify the most effective and practical myopia-control option for children, potentially slowing vision deterioration and reducing future eye-health risks.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. Side effects like light sensitivity or contact-lens intolerance may limit real-world use, and individual responses can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 348 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2023
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
5 to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Children age of 5-12 years old at their baseline exam * Children with a spherical equivalent refractive error of +0.50D (minimal hyperopia) to -7.50 D (high myopia) * Gestational age ≥ 32 weeks. * Birth weight \>1500g. Exclusion Criteria: * Current or previous form of myopia control * Current or previous use of bifocal, progressive- addition lenses, or multifocal contact lenses * Known atropine allergy or contact lens intolerance (allergy to only one can still allow enrollment in the other group) * Abnormality of cornea, lens, central retina, iris, or ciliary body * Current or prior history of manifest strabismus, amblyopia, or nystagmus * Current or previous myopia treatment with atropine, pirenzepine or another anti-muscarinic agent. * Current or previous use of bifocals, progressive-addition lenses, or multi-focal contact lenses. * Current or previous use of orthoK, rigid gas permeable, or other contact lenses being used to reduce myopia progression. * Abnormality of the cornea, lens, central retina, iris, or ciliary body. * Prior eyelid, strabismus, intraocular, or refractive surgery. * Down syndrome or cerebral palsy. * Diseases known to affect accommodation, vergence, or ocular motility (e.g., multiple sclerosis, Grave's disease, myasthenia gravis, diabetes mellitus, Parkinson's disease) * Existing ocular conditions (e.g., retinal disease, cataracts, ptosis) or systemic/neurodevelopmental conditions (e.g., Down syndrome) which may influence refractive development * Any condition that in the judgement of the investigator could potentially influence refractive development. * Existing conditions that may affect the long-term health of the eye or require regular pharmacologic treatment that may adversely interact with study medication (e.g., JIA, glaucoma, diabetes mellitus, pre-diabetes) * Inability to comprehend and/or perform any study-related clinical tests
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Myopia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A monocentre, Single-Arm trial to study the effect of lens inspired by myopia control solutions on the astigmatism of a child
- Can a lens put the brakes on worsening Short-Sightedness?
- Can a new lens implant sharpen vision for nearsighted eyes?
- LASIK gets a precision upgrade to sharpen night vision
- A daily eye drop might slow childhood nearsightedness. a trial puts it to the test.
- Can a single lens implant restore near and distance vision?